Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $35.12, but opened at $31.93. Nanobiotix shares last traded at $31.9330, with a volume of 28,232 shares traded.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NBTX. Guggenheim upped their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. UBS Group upped their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Nanobiotix presently has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Trading Down 10.8%

The stock’s fifty day simple moving average is $31.69 and its 200-day simple moving average is $25.25.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million for the quarter. On average, equities research analysts predict that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Nanobiotix

A number of hedge funds have recently bought and sold shares of NBTX. Millennium Management LLC bought a new stake in shares of Nanobiotix in the fourth quarter valued at about $390,000. Royal Bank of Canada lifted its stake in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the fourth quarter valued at about $220,000. Finally, Optiver Holding B.V. bought a new stake in shares of Nanobiotix in the third quarter valued at about $101,000. 38.81% of the stock is currently owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.